MONOVISC®

Administering Techniques

MONOVISC® is administered via a single intra-articular injection directly into the knee joint space. Proper technique is essential for optimal results and includes:

• Identifying the anatomical landmarks of the joint 
• Aspiration of any excess synovial fluid before injection 
• Using a sterile, 18–21 gauge needle to inject the product 
• Post-injection patient monitoring to confirm tolerability 

This procedure should only be performed by qualified healthcare professionals trained in joint injection protocols.

MONOVISC® Product Range

• MONOVISC® 4 mL Syringe: A single-use, prefilled syringe containing 88 mg of ultra-pure sodium hyaluronate in a 4 mL solution. Designed for one-time intra-articular injection for the knee. 

Currently, MONOVISC® is offered as a single-product formulation specifically tailored for osteoarthritis of the knee.

Side Effects

Most side effects are mild and short-term, including:

• Temporary joint stiffness or swelling 
• Mild pain or discomfort at the injection site 
• Redness or bruising around the knee area 

Serious reactions are extremely rare when sterile technique and proper patient screening are applied.

MONOVISC® vs Competition

MONOVISC® differs from other viscosupplements in several ways:

• It requires only one injection, whereas many competitors require three to five. 
• The non-animal-sourced HA formulation reduces immunogenicity risks. 
• Its patented cross-linking technology offers extended residence time and improved efficacy. 
• It is backed by robust clinical data and global regulatory approvals. 

Compared to other HA-based injectables used in osteoarthritis, MONOVISC® offers the advantage of convenience, compliance, and long-lasting relief—all essential attributes in modern pain management practices.